153 related articles for article (PubMed ID: 15550926)
1. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation.
Schauber-Plewa C; Simmons A; Tuerk MJ; Pacheco CD; Veres G
Gene Ther; 2005 Feb; 12(3):238-45. PubMed ID: 15550926
[TBL] [Abstract][Full Text] [Related]
2. Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.
Guibinga GH; Friedmann T
Mol Ther; 2005 Apr; 11(4):645-51. PubMed ID: 15771967
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro.
Schauber CA; Tuerk MJ; Pacheco CD; Escarpe PA; Veres G
Gene Ther; 2004 Feb; 11(3):266-75. PubMed ID: 14737086
[TBL] [Abstract][Full Text] [Related]
4. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.
DePolo NJ; Reed JD; Sheridan PL; Townsend K; Sauter SL; Jolly DJ; Dubensky TW
Mol Ther; 2000 Sep; 2(3):218-22. PubMed ID: 10985952
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.
Kaname Y; Tani H; Kataoka C; Shiokawa M; Taguwa S; Abe T; Moriishi K; Kinoshita T; Matsuura Y
J Virol; 2010 Apr; 84(7):3210-9. PubMed ID: 20071581
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors.
Hüser A; Rudolph M; Hofmann C
Nat Biotechnol; 2001 May; 19(5):451-5. PubMed ID: 11329015
[TBL] [Abstract][Full Text] [Related]
7. Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors.
Kremer KL; Dunning KR; Parsons DW; Anson DS
J Gene Med; 2007 May; 9(5):362-8. PubMed ID: 17380490
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer in human skin with different pseudotyped HIV-based vectors.
Hachiya A; Sriwiriyanont P; Patel A; Saito N; Ohuchi A; Kitahara T; Takema Y; Tsuboi R; Boissy RE; Visscher MO; Wilson JM; Kobinger GP
Gene Ther; 2007 Apr; 14(8):648-56. PubMed ID: 17268532
[TBL] [Abstract][Full Text] [Related]
9. Preparation of pseudotyped lentiviral vectors resistant to inactivation by serum complement.
Guibinga GH; Friedmann T
Cold Spring Harb Protoc; 2010 Jul; 2010(7):pdb.prot5420. PubMed ID: 20647353
[TBL] [Abstract][Full Text] [Related]
10. Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.
Liehl B; Hlavaty J; Moldzio R; Tonar Z; Unger H; Salmons B; Günzburg WH; Renner M
Gene Ther; 2007 Sep; 14(18):1330-43. PubMed ID: 17611586
[TBL] [Abstract][Full Text] [Related]
11. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.
McKay T; Patel M; Pickles RJ; Johnson LG; Olsen JC
Gene Ther; 2006 Apr; 13(8):715-24. PubMed ID: 16397505
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions.
Kahl CA; Pollok K; Haneline LS; Cornetta K
Mol Ther; 2005 Mar; 11(3):470-82. PubMed ID: 15727944
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent gene transduction using gammaretroviral and lentiviral vectors pseudotyped with chimeric vesicular stomatitis virus glycoprotein.
Kameyama Y; Kawabe Y; Ito A; Kamihira M
J Virol Methods; 2008 Oct; 153(1):49-54. PubMed ID: 18606189
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analyses of stability of simple and complex retroviral vectors.
Higashikawa F; Chang L
Virology; 2001 Feb; 280(1):124-31. PubMed ID: 11162826
[TBL] [Abstract][Full Text] [Related]
15. Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications.
Farley DC; Iqball S; Smith JC; Miskin JE; Kingsman SM; Mitrophanous KA
J Gene Med; 2007 May; 9(5):345-56. PubMed ID: 17366519
[TBL] [Abstract][Full Text] [Related]
16. A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors.
Zhang B; Xia HQ; Cleghorn G; Gobe G; West M; Wei MQ
Gene Ther; 2001 Nov; 8(22):1745-51. PubMed ID: 11892843
[TBL] [Abstract][Full Text] [Related]
17. Production and concentration of pseudotyped HIV-1-based gene transfer vectors.
Reiser J
Gene Ther; 2000 Jun; 7(11):910-3. PubMed ID: 10849549
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research.
Schambach A; Galla M; Modlich U; Will E; Chandra S; Reeves L; Colbert M; Williams DA; von Kalle C; Baum C
Exp Hematol; 2006 May; 34(5):588-92. PubMed ID: 16647564
[TBL] [Abstract][Full Text] [Related]
19. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
Engelstädter M; Buchholz CJ; Bobkova M; Steidl S; Merget-Millitzer H; Willemsen RA; Stitz J; Cichutek K
Gene Ther; 2001 Aug; 8(15):1202-6. PubMed ID: 11509952
[TBL] [Abstract][Full Text] [Related]
20. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.
Kyriakou CA; Yong KL; Benjamin R; Pizzey A; Dogan A; Singh N; Davidoff AM; Nathwani AC
J Gene Med; 2006 Mar; 8(3):253-64. PubMed ID: 16288493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
